Our philosophy: outsource to get going fast, insource when it's time to exit.
Don't let vetting vendors, personnel, and compliance stall what could be done in about three weeks.
I don't expect you to watch this whole video before applying, but it would be good to read this whole page before doing so.
Are you:
Not for you if you can't fund $30,000 of Meta and Google ads in month 1. This is licensed patient care under a brand you own.
Not ready to launch? Be an affiliate instead: promote one of our telehealth brands, and we'll support you in promoting it.
You've got three options. Two of them are bad.
Send your people to somebody else's brand. They keep the patients, the rebills, and the business. You get a cut, and the day you stop posting, it stops.
An attorney, a doctor network, a pharmacy deal, your own LegitScript, a site, a marketing team, a call center, and the compliance to not get fined. Past $50,000 and most of a year of vetting. If you get it right.
You own the brand, and the machine is already built: doctors, pharmacy, payments, compliance, a marketing team on Meta and Google, and a call center. Outsource to get going fast, insource when it's time to exit. Live and taking patients in about three weeks.
Before anything else, the money. Put in your ad budget and what a patient costs, or the audience you already have, and how long patients stay. Your monthly profit shows up, with the exit value underneath it. Pick a scenario, or build your own. If we run it for you, you pay once, then nothing until the business clears $50,000 of cumulative net profit. If you run it yourself, there is no share at all.
Same 1,000 people, valued two ways. As a research brand they order about $250 every other month, roughly $1.5M a year at the high margins these brands run, and they trade around 3x profit. Licensed, those same people are on a $350 monthly protocol with cross-sells, roughly $4.2M a year, and telehealth trades on revenue. The multiple is a notch better. The monetization is a lot better.
Same 1,000 people, and the licensed brand is worth roughly four times more.
Most of the gap is monetization, not the multiple. The licensed brand earns about 2.8x more from the same people, because a $350 monthly protocol with cross-sells beats $250 every other month. The multiple only adds a little on top: roughly 3x revenue for licensed telehealth against about 2.3x for a research brand. A research brand is a good business. This is a bigger one, built on the customers you already have.
Strategics, private equity, and operators all shop licensed telehealth. A research brand sells into a thin, nervous pool, and a small pool prices low.
A monthly protocol with a doctor behind it retains far better than sporadic vial orders. Buyers pay up for revenue that stays.
Same patient, more to sell: lab panels, supplements, ED, hair loss, HRT. What a patient is worth expands instead of flatlining.
Retention and expansion are what a multiple prices. Which is why 3x is the conservative read here, not the optimistic one.
Illustrative model only. You choose every input, so the output is your assumption, not a projection, forecast, guarantee, or promise of earnings. Per-patient figures assume protocols priced at market (tirzepatide $399, semaglutide $299, hormone protocols $159 to $199) less medication at our negotiated rates, clinician fees, and processing, then the ad budget and fixed business expenses you set (default $5,000 a month), with ad-driven patients costing what you set on the acquisition slider (default $350, the cold-traffic range in this category). Nothing is deducted for our share, which only starts after your cumulative profit clears the threshold on your agreement. Exit value uses roughly 3x revenue once a brand is past $1 million a year, and 3x profit below that. What a company earns or sells for depends on the market, its margins, retention, and execution.
Like your numbers? The call is where the team runs them against your market and budget.
Payments and distribution on one side. Telehealth operations on the other. An operating crew underneath.
Behind them, the operating crew. A marketing team on Meta and Google, a call center working every lead, finance, patient-side care coordination, cart recovery, creative, and vendors.
Our biggest payday is your exit. When we run it for you, we charge once for the build, then share in the profit and take 20% of the sale. Both are worth nothing unless the brand works, and the big one only lands if it's worth buying.
sermorelin.com alone already draws around 20,000 organic visitors a month.
Not mockups. Live category properties, pulling organic traffic right now. Tap one.

You keep the equity in your own brand, and you can exit it on your own. Mark and I hold 20% of the upside on every brand we run, plus the domain portfolio and the distribution, and we take all of it to one big exit together. We get paid for the build along the way, but the prize we're playing for is the same one you're playing for.
The same 20% on the profit and on the sale. Neither pays until the business does.
Everyone else selling a platform is saying buy from us, and good luck. Here's the keys, good luck driving this rocket ship. Oh, I'm not an astronaut. I'm going to crash. That's what most of these brands end up doing.Mark, operations partner, on the other platforms
Each of these is a wall that stops people from ever starting. We take all of them down in the build, and the build is the same however much of it we run afterward.
Wyoming LLC, business bank account approved in about a day, Stripe live before LegitScript, legally.
Application prepped and filed in week one, driven to certification in about two to three weeks. It is the gate to going live.
Name, domain strategy, and a conversion-built site, live and compliant.
White-label telehealth platform at our negotiated rate, catalog at cost, zero markup.
Tracking, email, text, automations, live dashboards, and a Slack channel with our team inside.
Your intake funnel launched with paid traffic behind it from day one, built around the one or two products you lead with.
Meta and Google campaigns built and managed on your budget, and a call center working every lead that stalls before finishing intake.
Refill automations and win-back flows from day one. Recurring revenue is the asset; this defends it.
Finance, patient-side care coordination, cart recovery, creative, from Day 30. Insource any of it when it's time to exit.
Quarterly audits keeping your books the way an acquirer reads them, from month one, when we run it for you.
The same decision, mapped side by side.
| A platform, alone | A platform + an agency | The launched brand, with the teamus | |
|---|---|---|---|
| Who builds your brand | You, alone | The agency, at their pace | Our team, in week one |
| Who gets you certified | You | Usually nobody | Us, filed in week one |
| Who brings the first patients | Nobody | Ads, once you fund them | Our marketing team and call center, on your ad budget, from launch day |
| Who runs it after launch | You | You; they run the ads | You with us on call, or our operating team, decided on your call |
| How they get paid | Setup, then fees on every order, win or lose | Every month, win or lose | Once for the build; a share only if we run it and only after it clears a profit threshold |
| Who is paid to help you sell | Nobody | Nobody | We are, when we run it. Books kept diligence-ready from month one, and our share only pays if the sale happens |
Three things, in this order. No patients move until the third one clears, and we would rather you knew that now than found out on the call.
An onboarding call to pull your brand references, your hero products, and the people in your orbit. Then about a week of build: the deck, the logo, the custom site, the intake wired to the prescriber network and pharmacy. Built to your brand, not a template with your name on it.
Certification is the gate. Nobody onboards a patient until it clears, and it usually takes two to three weeks. That window is not dead time: your entity, bank, processing and ad accounts go up, you train on the platform, and the launch assets get made. But no patient, no prescription, no charge until the certificate is in hand.
Intake opens, the first campaigns go out, and the daily calls run until your first ten patients. Paid traffic runs from day one on your Meta and Google budget, the marketing team optimizes it, and the call center works every lead that stalls. Any audience you bring gets a launch push on top. Section 06 is your job description from here.
One company, one chart. You own the brand, the entity, the ad budget, and every strategic call. We sit under you as the fractional COO and CTO, with customer service under us. Clinicians sit beside the company, not under anyone, because they prescribe on their own judgment. The only decision left is how much of the recurring list we run for you, and that is decided on your call.
Run this list yourself with us on call, or we run it as your operating team and share in the upside. Same build either way. Which one fits you is the team's recommendation on your call.
You don't have to be the face. Front it yourself if you want to, put a creator on it, or stay behind the brand entirely. You fund the ad budget. Everything else is on us.
Every brand gets the same build: site, funnel, LegitScript, rails, network, launch. The difference is who runs the business after launch and how the team is paid. Terms are set on your call.
One flat engagement, paid once. No equity, no profit share, no monthly fee. The team is in it with you for a fixed term of three or six months, then you run it alone.
A subsidised startup cost, paid once, then the team runs the company with you and is paid only from profit: a monthly operating minimum or a share of net profit, whichever is greater, after the business clears a profit threshold. Plus a share of the exit if you ever sell.
Every starter platform carries the same short menu: semaglutide, tirzepatide, testosterone, and the same pills everyone has seen a hundred ads for. Identical brands, identical products, margin bleeding out on price. Three things separate yours.
We partner with doctor networks that prescribe what the big platforms won't touch: BPC-157, GHK-Cu, NAD+, sermorelin, TB-500, CJC-1295, and a formulary that runs dozens deep. Most are not FDA-approved, and nobody pretends otherwise. Doctors prescribe them on their own clinical judgment, where their state boards allow it, and because many of these compounds can't be patented, no pharma giant has a billion-dollar reason to clear the field.
The drugs are commodities. The difference is the blood work: full panels, read by a licensed team, turned into a plan for each patient. People stay because somebody is tracking what's happening in their body. A research brand can't even suggest a blood test without implying human use.
A licensed brand gets to bolt on the next generation of medicine as it lands: advanced lab assessments, less invasive mitochondrial testing, AI-assisted diagnostics. Every new tool raises what your brand is worth. Research brands are locked out of that entire world.
Patients rebill every month whether you worked that day or not. Your revenue arrives on a schedule instead of starting from zero every morning. Your business has a clean profit and loss, the kind a buyer reads and likes.
And you are not refreshing a processor dashboard praying it still works, because nobody freezes a doctor writing a valid prescription. You own something now. Not a hustle that can disappear. An asset you could sell. And every quarter, your books get reviewed the way an acquirer will one day read them, because a team that shares in your exit has every reason to keep you sellable.
And the peptide wave hasn't broken yet. GLP-1s are already racing toward 50% adoption. Peptides are still under 5%, the exact spot GLP-1s were in right before they went mainstream. Every fitness influencer is about to be talking about peptides, and Washington is deciding on peptide compounding right now, with the card networks, the banks, and the VCs all waiting on the answer before the money floods in. Get in front of the wave now, and you are the brand everyone else chases later.
They come with the operated seat, and the refund schedule comes with every agreement.
Live and taking patients when LegitScript clears, with your first campaigns in-market within two weeks of certification and in any case within 45 days of kickoff, or the team keeps working at no further cost until it's done. Late weeks are on us. (Your side: brand decision made early, documents signed on schedule, training attended.)
Daily calls with our team until your first ten patients are in. However long it takes.
Our share is worth zero if your brand goes nowhere. The fee pays for the build; the share only pays if you win. Their guarantee is a refund policy. Ours is the deal itself, plus a milestone refund schedule written into every agreement.
All three come with the seat. Booking a call takes a minute.
Ten founding seats for the brands we run. Grab a time below. On the call, the team looks at your market and budget, maps your launch, and runs your numbers, and you know by the end of it, either way.